Global Blood Therapeutics is focused on developing novel, orally-available therapeutics for chronic blood diseases. The company is addressing severe, non-malignant blood-based diseases for which there are currently no effective cures and only extremely limited therapeutic options. Learn More

Spotlight on Sickle Cell Disease 

Global Blood Therapeutics’ lead program is in sickle cell disease (SCD), which impacts approximately 100,000 patients in the U.S. and more than 7 million worldwide. There are very limited treatment options for patients with SCD, and none that address the underlying cause of the disease.

Learn More

Recent News


Global Blood Therapeutics Names Ted W. Love as CEO Read More >>


Global Blood Therapeutics Presents New Preclinical Data on Lead Sickle Cell Disease Drug Candidate, GTx011, at American Society of Hematology Annual Meeting Read More >>


Global Blood Therapeutics to Present First Data on its Lead Sickle Cell Disease Program at 55th ASH Annual Meeting Read More >>